...own the only FDA approved treatment plus a pipeline for other treatments
In a recently completed phase 2 clinical trial, MYMD-1 met both of its primary endpoints, reducing the TNF-alpha, IL-6 and sTNFR1 biomarkers that are common in several chronic inflammatory diseases while meeting all secondary endpoints for safety and tolerability standards. The next-generation treatment met the secondary endpoints needed to advance the sarcopenia clinical program. The full study results will be released in 2024.
"We are encouraged by the reduction of inflammatory markers along with the favorable safety profile demonstrated in this study of an oral TNF-alpha inhibitor," said Chris Chapman, M.D., President, Director, and Chief Medical Officer at MyMD. "Sarcopenia can significantly affect people as they age, and there are currently no approved treatments for the condition. A selective, oral treatment that reduces TNF-alpha and inflammation and does not require infusion or injection would be a welcome advance for this population."
If approved, MYMD-1 could become the first FDA-approved drug for sarcopenia, which causes patients to have a decline in muscle mass, among other symptoms.